The complement system is a key part of the innate and adaptive immune system and plays a major role in homeostasis by clearing altered host cells and invading pathogens. Compstatin, a 13-residue peptide, is an effective inhibitor of the activation of complement component C3 with IC50 value of 12 μM and thus blocks a central and crucial step in the complement cascade[1]. In vitro studies of compstatin in human blood indicated that a major pathway of biotransformation was the removal of Ile1, which could be blocked by N-acetylation of the peptide[2]. Subsequent interaction analysis confirmed that compstatin binds NHP C3 (baboon) and human C3 with similar affinity, but it does not bind to mouse or rat C3[3]. Compstatin produced complete inhibition at a total dose of 21 mg/kg when given as a combination of bolus injection and infusion. It completely inhibited in vivo heparin/protamine-induced complement activation without adverse effects on heart rate or systemic arterial, central venous, and pulmonary arterial pressures[4].
作用机制
The crystal structure reveals that the compstatin-binding site is formed by the macroglobulin (MG) domains 4 and 5[1].
Compstatin/坎普他汀 细胞研究
细胞系
浓度
检测类型
检测时间
活性说明
数据源
RPE cells
50 uM
Function assay
Inhibition of complement activation in human fetal RPE cells assessed as reduction in C5b-9 formation at 50 uM by fluorescence assay in presence of complement-competant human serum
Inhibition of complement activation in human fetal RPE cells assessed as reduction in C5b-9 formation at 50 uM by fluorescence assay in presence of complement-competant human serum
搜索
